Visilizumab is a humanized monoclonal antibody that targets CD3 receptor. Visilizumab is used as an immunosuppressive agent with potential activity for ulcerative colitis and Crohn's disease.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.